November 10, 2021 07:26 AM ESTUpdated November 11, 03:24 PM

Ligand to split in half, spinning OmniAb platform into its own company

Nicole DeFeudis

Editor

It’s been six years since Ligand Pharmaceuticals plumped down $178 million for OMT and its antibody discovery platform OmniAb. Now, with a slate of big …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Ligand to split in half, spinning OmniAb platform into its own company

Nicole DeFeudis

Editor

Sign up to read this article for free.

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

Novartis to cut 139 jobs in NJ as part of commercial refocus

Advanz Pharma faces revocation of European authorization for liver disease drug Ocaliva

Applied Therapeutics' rare disease drug gets a CRL

Bristol Myers sues the federal government over 340B, following other drugmakers

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life

Lig­and to split in half, spin­ning Om­niAb plat­form in­to its own com­pa­ny

Nicole DeFeudis

Editor

Sign up to read this article for free.

more like this

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Ad­vanz Phar­ma faces re­vo­ca­tion of Eu­ro­pean au­tho­riza­tion for liv­er dis­ease drug Ocali­va

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

Ligand to split in half, spinning OmniAb platform into its own company

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

Novartis to cut 139 jobs in NJ as part of commercial refocus

Advanz Pharma faces revocation of European authorization for liver disease drug Ocaliva

Applied Therapeutics' rare disease drug gets a CRL

Bristol Myers sues the federal government over 340B, following other drugmakers

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life